Contact A Counsellor

counsellor button


teen suicide icon


panic anxiety icon

panic anxiety icon

#MindfulMondays with Miss SA

teen suicide icon


Research on Depression in the Workplace.

For more information please click here



email subscribers list

To subscribe to SADAG's newsletter, click here

To view previous newsletters - click here


Mental Health Matters Journal for Psychiatrists & GP's

MHM Volume 8 Issue1

Click here for more info


journalists crew making newspaper

If you are a journalist writing a story contact Kayla on 011 234 4837  media@anxiety.org.za


MySchool Facebook banner Nov

It’s the small things that make a BIG difference. Sign up for the “My School | My Village | My Planet” Card and start making a difference to Mental Health in South Africa today.

Click Here


cope with cancer book

Literacy is a luxury that many of us take for granted. That is why SADAG created SPEAKING BOOKS and revolutionized the way healthcare information is delivered to low literacy communities.

The customizable 16-page book, read by local celebrity audio recordings, ensures that vital health and social messages can be seen, heard, read and understood by everyone across the world.

We started with books on Teen Suicide prevention , HIV, AIDS and Depression, Understanding Mental Health and have developed over 100+ titles, such as TB, Malaria, Polio, Vaccines for over 45 countries.

suicide speaking book

NEW YORK (Reuters Health) - For people suffering from depression that
doesn't respond to treatment with one type of antidepressant, switching to a
different type may be the best treatment, according to a new report.

Relatively new antidepressants such as Prozac and Zoloft, for example, are
called selective serotonin reuptake inhibitors or SSRIs. In recent clinical
trials, only about a third of depressed patients achieved remission with
SSRI treatment, the authors explain, but there is little consensus among
psychiatrists about the best treatment for patients when an SSRI doesn't

To look into this, Dr. George I. Papakostas from Harvard Medical School,
Boston, and his associates conducted an analysis of four clinical trials
that compared a switch to a second SSRI versus a non-SSRI antidepressant for
SSRI-resistant major depression.

The pooled data included 1496 patients who had not responded to treatment
with one SSRI and were subsequently randomly assigned to treatment with
another SSRI or a non-SSRI antidepressant.

Patients randomized to switch to a non-SSRI antidepressant were slightly
more likely to experience remission than patients who were switched to a
second SSRI, the researchers report in the medical journal Biological

However, the non-SSRI antidepressants were somewhat less well tolerated than
the SSRIs.

The results indicate that current treatments for depression are still less
than ideal. "There continues to be a pressing need to introduce new
antidepressant medications," comments Dr. John Krystal, the journal's

SOURCE: Biological Psychiatry, April 1, 2008.


Our Sponsors

Our Partners